The National Oncologic PET Registry is no longer accepting new FDG-PET cases, but it will continue gathering data on NaF-PET imaging. NOPR launched in 2006 with the goal of assessing the utility of FDG-PET in patient treatment planning and outcomes, and three years later, CMS broadened coverage for nine cancers and added two. It's possible the registry will turn to focus on the study of beta-amyloid imaging, but SNMMI President Dr. Gary Dillehay noted there are special challenges with Alzheimer's imaging that aren't encountered in oncology. "The benefit for the oncology patient is that you can find out within a year or two whether you are making a significant change in patient management or patient outcomes. ... We are not convinced that this particular method will work with dementia evaluation because the timeline is too long before you can confirm what you saw with an amyloid study," Dillehay said.